BS_1A6MQ9ZA
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 20.9592641261498
- age_years
- 15.488
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.587
- MTORC1_SIGNALING+0.553
- MYC_TARGETS_V1+0.537
- INTERFERON_ALPHA_RESPONSE+0.520
- OXIDATIVE_PHOSPHORYLATION+0.518
- E2F_TARGETS+0.491
- G2M_CHECKPOINT+0.451
- UNFOLDED_PROTEIN_RESPONSE+0.451
- ANDROGEN_RESPONSE+0.425
- INTERFERON_GAMMA_RESPONSE+0.372
Top 10 suppressed
- APICAL_SURFACE-0.392
- KRAS_SIGNALING_DN-0.346
- WNT_BETA_CATENIN_SIGNALING-0.288
- MYOGENESIS-0.214
- ESTROGEN_RESPONSE_LATE-0.088
- ALLOGRAFT_REJECTION-0.066
- XENOBIOTIC_METABOLISM-0.054
- BILE_ACID_METABOLISM-0.044
- ESTROGEN_RESPONSE_EARLY-0.042
- IL2_STAT5_SIGNALING-0.036
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_2EN3X6HB | high-grade glioma | — | 0.923 |
| 2 | SJEPD030391_D1.RNA-Seq | EPN | Supratentorial EPN | 0.890 |
| 3 | 54B7F258-FE9A-4EFE-87FB-465D587B1170 | — | — | 0.876 |
| 4 | SRR934929 | — | — | 0.868 |
| 5 | MNG1191 | — | — | 0.868 |
| 6 | f9c74189-6bdc-49b9-b984-917ffe2b097d | — | — | 0.865 |
| 7 | TCGA-78-7145-01A-11R-2039-07 | — | cohortA1 | 0.865 |
| 8 | TCGA-C4-A0F0-01A-12R-A10U-07 | — | — | 0.862 |
| 9 | C3N-00574 | — | cohortA4 | 0.861 |
| 10 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.587 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.553 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.537 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.518 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.491 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.451 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.451 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.425 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.372 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.357 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.353 | Inavolisib | — uncovered |
| HYPOXIA | 0.349 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.306 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.301 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.295 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.285 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.269 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.266 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.257 | Inavolisib | — uncovered |